Green Signal for Alembic: Rivaroxaban Tablets Cleared for Takeoff in the US

Alembic Pharmaceuticals has achieved final US Food and Drug Administration (USFDA) approvals for its Rivaroxaban tablets, which is an important achievement by the company in the high-value US generics industry. The four strengths are covered by the approvals and place Alembic at a position where it can penetrate a multi-billion dollar market for this commonly prescribed anticoagulant.

 

Details of the Approval

Market Opportunity

Strategic Impact for Alembic

Stock Market Reaction

With earlier announcements on Rivaroxaban approvals, the share price of Alembic Pharma has consistently made significant gains, demonstrating investor faith in its US growth strategy.

 

Conclusion

Alembic Pharma's second and last USFDA clearance of Rivaroxaban tablets in various strengths is a big win, opening the gates to a highly priced market and further strengthening the company's presence in the global generic market. 

 

Sources: Business Upturn, Business Today, Business Standard, Bajaj Broking